Related Experiment Videos
Zoledronic acid: a new parenteral bisphosphonate
1Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, Philadelphia, Pennsylvania 19104, USA.
Clinical Therapeutics
|December 25, 2003
Summary
Zoledronic acid effectively treats hypercalcemia of malignancy and bone complications from cancer metastasis. This nitrogen-containing bisphosphonate is well-tolerated and shows superior efficacy compared to pamidronate in clinical studies.
Area of Science:
- Oncology
- Pharmacology
- Bone Metabolism
Background:
- Bisphosphonates are crucial for managing cancer-related bone complications like hypercalcemia and metastatic bone disease.
- Effective palliation of skeletal-related events is a key goal in advanced cancer care.
Purpose of the Study:
- To review the pharmacological properties of zoledronic acid (zoledronate).
- To synthesize findings from preclinical and clinical research on zoledronic acid for skeletal disorders.
Main Methods:
- Literature search of MEDLINE and International Pharmaceutical Abstracts (1966-2003).
- Inclusion of abstract proceedings from the American Society of Clinical Oncology (1997-2002).
- Keywords used: zoledronic acid, zoledronate, Zometa, 118072-93-8.
Main Results:
- Zoledronic acid demonstrated higher complete response rates for hypercalcemia of malignancy versus pamidronate.
- It showed comparable efficacy to pamidronate in delaying skeletal-related events in breast cancer and multiple myeloma.
- Zoledronic acid reduced skeletal-related events and fractures in prostate cancer with bone metastases and delayed events in other solid tumors.
Conclusions:
- Zoledronic acid is an effective treatment for hypercalcemia of malignancy.
- It is also effective for skeletal complications associated with metastatic bone disease.
- The drug is generally well-tolerated by patients.